GENESIS AI Aktie

 

Former Google DeepMind Director brings over two decades of AI research expertise and industrial leadership to Genesis' AI platform and high-performing research teamsBURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for the treatment of severe diseases, today announced the appointment of Aleksandra Faust, Ph.D., as Chief AI Officer. Dr. Faust joins Genesis with more than 20 years of leadership experience in the AI and tech industries, developing machine learning (ML) for complex systems such as robotics and autonomous vehicles. She most recently served as Director of Research at Google DeepMind, overseeing foundational model learning research and contributing to Gemini and to generalist web agents, among many other key innovations in her tenure. In her previous roles, she co-founded reinforcement learning research at Google Brain, founded task and motion planning research in Robotics at Google, led mac...

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA3719571018 Genesis AI Corp. 12.03.2025 CA3719572008 Genesis AI Corp. 13.03.2025 Tausch 10:1 CA90022K1003 King Copper Discovery Corp. 12.03.2025 CA4947261026 King Copper Discovery Corp. 13.03.2025 Tausch 1:1 CA78412Y2024 SBD Capital Corp. 12.03.2025 CA78412Y3014 SBD Capital Corp. 13.03.2025 Tausch 10:1 CA48132D2005 Juggernaut Exploration Ltd. 12.03.2025 CA48132D3094 Juggernaut Exploration Ltd. 13.03.2025 Tausch 10:1...